Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

Nasr, 2004, Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis, Kidney Int, 65, 85, 10.1111/j.1523-1755.2004.00365.x Bridoux, 2015, Diagnosis of monoclonal gammopathy of renal significance, Kidney Int, 87, 698, 10.1038/ki.2014.408 Nasr, 2009, Proliferative glomerulonephritis with monoclonal IgG deposits, J Am Soc Nephrol, 20, 2055, 10.1681/ASN.2009010110 Gumber, 2018, A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits, Kidney Int, 94, 199, 10.1016/j.kint.2018.02.020 Hogan, 2019, Dysproteinemia and the kidney: core curriculum 2019, Am J Kidney Dis, 74, 822, 10.1053/j.ajkd.2019.04.029 Nasr, 2020, Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone, Kidney Int, 97, 589, 10.1016/j.kint.2019.10.025 Leung, 2021, Monoclonal gammopathy of renal significance, N Engl J Med, 384, 1931, 10.1056/NEJMra1810907 Zand, 2021, Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits, J Am Soc Nephrol, 32, 1163, 10.1681/ASN.2020101541 Almaani, 2021, Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits, Kidney Int Rep, 6, 2203, 10.1016/j.ekir.2021.05.008 Wang, 2008, Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure, Blood, 112, 4445, 10.1182/blood-2008-02-141614 Warsame, 2020, Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis, Blood Cancer J, 10, 4, 10.1038/s41408-019-0266-9 Houan, 2020, Lenalidomide plus dexamethasone for proliferative glomerulonephritis with monoclonal immunoglobulin deposits, Chin J Nephrol, 36, 441 Troyanov, 2005, Focal and segmental glomerulosclerosis: definition and relevance of a partial remission, J Am Soc Nephrol, 16, 1061, 10.1681/ASN.2004070593 Palladini, 2005, The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL), Blood, 105, 2949, 10.1182/blood-2004-08-3231 Dimopoulosa, 2013, How lenalidomide is changing the treatment of patients with multiple myeloma, Crit Rev Oncol Hematol, 88, s23, 10.1016/j.critrevonc.2013.05.013 Treon, 2004, Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia, Ann Oncol, 15, 1481, 10.1093/annonc/mdh403 Sethi, 2013, Monoclonal gammopathy-associated proliferative glomerulonephritis, Mayo Clin Proc, 88, 1284, 10.1016/j.mayocp.2013.08.002 Hutchison, 2008, Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease, Clin J Am Soc Nephrol, 3, 1684, 10.2215/CJN.02290508 Coresh, 2014, Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality, JAMA, 311, 2518, 10.1001/jama.2014.6634 Burwick, 2019, Glucocorticoids in multiple myeloma: past, present, and future, Ann Hematol, 98, 19, 10.1007/s00277-018-3465-8 Tsai, 2019, Low serum C3 level, high neutrophil-lymphocyte-ratio, and high platelet-lymphocyte-ratio all predicted poor long-term renal survivals in biopsy-confirmed idiopathic membranous nephropathy, Sci Rep, 9, 6209, 10.1038/s41598-019-42689-7 Zhang, 2017, IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3, Sci Rep, 7, 5400, 10.1038/s41598-017-05704-3 Terpos, 2015, European myeloma Network guidelines for the management of multiple myeloma-related complications, Haematologica, 100, 1254, 10.3324/haematol.2014.117176 Moreau, 2016, Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma, N Engl J Med, 374, 1621, 10.1056/NEJMoa1516282 Dote, 2019, Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study, Leuk Lymphoma, 60, 2975, 10.1080/10428194.2019.1608531 Chanan-Khan, 2012, Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment, Clin Cancer Res, 18, 2145, 10.1158/1078-0432.CCR-11-0498 Smyth, 2019, Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure, Ir J Med Sci, 188, 1079, 10.1007/s11845-018-1951-6